As compared with VCaP tumors from null × CD3–treated mice, KLK2 × CD3 treatment resulted in increased CD8+ and CD4+ T-cell infiltration, with a concomitant reduction of KLK2+ tumor cells as measured by the detection of KLK2 and cytokeratin. This evidence concerns the gene CD8A and neoplasm.